Targeting Anhedonia in Cocaine Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
Cocaine-Related DisordersAnhedonia
Interventions
DRUG

d-amphetamine

Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.

BEHAVIORAL

Contingency management

Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.

DRUG

Placebo (for d-amphetamine)

60 mg of riboflavin and cornstarch as needed.

Trial Locations (1)

60607

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

The University of Texas Health Science Center, Houston

OTHER

lead

University of Illinois at Chicago

OTHER

NCT02773212 - Targeting Anhedonia in Cocaine Use Disorder | Biotech Hunter | Biotech Hunter